EyePoint Pharmaceuticals

Press Releases

pSivida Corp. Reports Patient Access Scheme Being Developed by Alimera to Address Cost Concerns Following Negative Final Draft Guidance by U.K.'s NICE for ILUVIEN® for DME
Nov 29, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) issued
pSivida Corp. Reports First Quarter Fiscal Year 2013 Results
Nov 08, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its first quarter ended September 30, 2012 .
pSivida Corp Announces First Quarter 2013 Financial Results Release Date and Conference Call Information
Nov 01, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the first quarter of fiscal year 2013 will be released after the
pSivida CEO to Discuss Sustained Delivery and Nanotechnology in Ophthalmology at Upcoming Massachusetts Biotechnology Council Meeting
Oct 15, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV)(ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its President and CEO, Dr. Paul Ashton , will discuss "Cross Fertilization: Sustained Delivery
pSivida Corp. Reports Fourth Quarter and Fiscal Year 2012 Results
Sep 24, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced financial results for its fourth quarter and fiscal year ended June 30, 2012 .
pSivida Corp. Announces Fourth Quarter and Fiscal Year 2012 Financial Results Release Date and Conference Call Information
Sep 17, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its financial results for the fourth quarter and fiscal year 2012 will be released after the
pSivida Corp. Reports U.K. National Institute for Health and Clinical Evidence Accepts ILUVIEN® Subgroup Data for Review
Sep 05, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that the United Kingdom's National Institute for Health and Clinical Excellence (NICE) has
pSivida CEO to Discuss Sustained Delivery and Nanotechnology in Ophthalmology at Drug Delivery Technologies & Formulation Conference in Switzerland
Aug 29, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that Dr. Paul Ashton , President and CEO, has been invited to participate as a distinguished
pSivida to Present at Two Investment Conferences in September
Aug 28, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it will present at two upcoming investor conferences in September.
pSivida Corp. Announces Closing of $5.36 Million Registered Direct Financing
Aug 08, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it closed the previously-announced securities purchase agreement with institutional
pSivida Corp. Announces $5.36 Million Registered Direct Financing
Aug 02, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV ) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, announced today that it has entered into a securities purchase agreement with institutional investors to raise
pSivida Corp. Reports Alimera's Intention to Resubmit Application to FDA for ILUVIEN® in DME Using Data from Completed Trials
Aug 01, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today reported that its licensee Alimera Sciences, Inc. has indicated its intention to resubmit its application
pSivida Corp. Announces Tech Evaluation Agreement for Tethadur™ Protein/Antibody Delivery System with Leading Biopharmaceutical Company
Jul 30, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that it has signed a funded technology evaluation agreement with a leading global
pSivida Corp. Announces Germany Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema
Jul 26, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the Federal Ministry of Health of Germany (Bundesministerium fur Gesundheit, BfArM) has granted
pSivida Corp. Receives FDA Clearance for Pivotal Trials for Injectable Sustained-Release Micro-Insert to Treat Uveitis
Jul 19, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND)
pSivida Corp. Announces France Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema
Jul 18, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the National Security Agency of Medicines and Health Products (L'Agence Nationale de Sécurité du
pSivida's Partner Alimera Sciences Announces an Agreement to Raise Capital to Fund the Development and Commercialization of ILUVIEN®
Jul 18, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced that its partner Alimera Sciences disclosed an agreement for a $40 million equity financing.
pSivida Corp. Announces Enrollment of First Patient in Uveitis Trial
Jun 28, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV)(ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the enrollment of the first patient in an investigator-sponsored clinical trial of its injectable
pSivida Corp. Announces Issuance of US Patent for Inserter to Be Used in Planned Phase III Uveitis Trials
Jun 06, 2012
WATERTOWN, MASS .--(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced it has been issued US patent No. 8,192,408 titled "Ocular Trocar Assembly" for a new inserter
pSivida Corp. Announces Portugal Grants ILUVIEN® Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema
Jun 05, 2012
WATERTOWN, Mass. --(BUSINESS WIRE)-- pSivida Corp. (NASDAQ: PSDV) (ASX: PVA), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the National Authority of Medicines and Health Products (Autoridade Nacional do Medicamento e
Displaying 161 - 180 of 303
EyePoint Pharmaceuticals